Nyxoah-Inspire Patent Dispute Returns as Company Shares Close at $0.8999
Key Facts
A default judgment in Nyxoah’s favor against Inspire Medical Systems in the patent case before the Munich court could not be verified. In the last trading session before the date of the report, Nyxoah shares closed at $0.8999 on November 17, 2026, according to EL7 data. Inspire Medical Systems shares closed at $59.41 on the same day. These prices, by themselves, do not provide evidence that a court ruling was issued or that it affected either stock. The documented dispute traces back to two lawsuits Nyxoah filed with the Unified Patent Court in Munich.
Nyxoah’s annual report said the company filed the lawsuits on December 1, 2025, against Inspire and Inspire Medical Systems Europe GmbH, alleging that the Inspire IV system infringes two European patents. The lawsuits concern patents EP 2 760 528 B1 and EP 2 760 534 B1. The company sought damages and an injunction, according to the annual report. This establishes the basis of the dispute and the relief Nyxoah requested, but it does not establish that a default judgment was issued in the current case. No documented details are available here about the terms of a ruling, damages or an injunction issued by the court.
Nyxoah develops nerve stimulation devices to treat sleep apnea; the company describes its Genio device as a neurostimulator with no battery or implanted wires. According to the device information page, Genio stimulates the hypoglossal nerve on both sides to help keep the upper airway open during sleep. The dispute recorded in the annual report concerns Nyxoah’s claim regarding the Inspire IV system and two European patents. This context describes the nature of the companies’ products and the basis of the lawsuit; it is not evidence of a legal outcome. In a separate case in the United States, Inspire said in its third-quarter filing that Nyxoah’s lawsuit concerning Inspire patents remains ongoing.
Inspire said in its filing that it could not predict the outcome of the U.S. lawsuit or estimate the range of potential losses, given the current status and the uncertainty inherent in litigation. On the business front, the company reported revenue of $206.695 million in the third quarter of 2026, compared with $224.501 million in the same period of 2025. In September, the company narrowed its fiscal 2026 revenue outlook to a range of $850–860 million, from its previous range of $835–875 million. These figures provide context on Inspire’s business performance and outlook and do not establish a link between its business results and the legal dispute. The available information did not include a specific date for the next court proceeding in the Munich case.